Life Sciences

Shared Investigator Platform (SIP) Strengths And Struggles

At any given time, a principal investigator (PI) can be working on one or more studies for a single sponsor company, or multiple studies for multiple sponsors.

Likewise, each sponsor runs its clinical trials its own way, using its preferred technology and processes. And, often times, the technology and/or processes differ from study to study, depending on how long a study has been running and whether it is being managed in-house or by a contract research organization (CRO) partner.

Life Sciences - How Artificial Intelligence Can Enhance the Clinical Data Review and Cleaning Process
How Artificial Intelligence Can Enhance the Clinical Data Review and Cleaning Process

This guide analyzes how artificial intelligence – including machine learning – can be used by pharmaceutical and medical device companies to improve the clinical data review and cleansing process.

Get the Guide

As you can imagine, given all of those variables, the life of a PI can be incredibly complex, confusing, and burdensome, which inevitably detracts from his/her ability to efficiently and effectively conduct life-changing research.

Given how valuable PIs are to sponsor companies, a handful of industry leaders have joined forces to improve the investigator experience, regardless of the study or sponsor company in question. These pioneers are members of TransCelerate BioPharma Inc., and include AbbVie, Allergan, Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, EMD Serono Merck, GlaxoSmithKline, Johnson & Johnson, Lilly, Merck & Co., Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Shionogi, and UCB.

One of the initial accomplishments of this do-gooder posse was the creation of a Shared Investigator Platform (SIP), designed to be a single destination for investigators and site personnel. The vision for SIP includes single sign-on (SSO) user authentication, consistent business processes, and standardized technology to support those processes.

While the vision is brilliant, the challenge is in the getting there. How can a sponsor – with technologies and processes in place and studies in progress – transition to using SIP without disrupting current operations or overburdening site personnel?

We recently helped one of the consortium members answer this question. If you’re interested in learning how we can help you do the same, simply fill out this form.

About the Author

Marin joined the life sciences industry in 2001. Over the course of her tenure, she has held roles in clinical finance, IT, quality assurance, and validation. The diversity of her experience provides her with a unique perspective on the interconnectedness of this complex, multi-faceted industry. Marin Richeson is a lead business consultant in Perficient's life sciences practice.

More from this Author

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Subscribe to the Weekly Blog Digest:

Sign Up
Categories